ARS Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US82835W1080

SecuritySPRY / ARS Pharmaceuticals, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership1,773,188 shares
Latest Disclosed Value $ 14,238,699
Citadel Advisors Llc ownership in SPRY / ARS Pharmaceuticals, Inc.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 1,773,188 shares of ARS Pharmaceuticals, Inc. (US:SPRY) valued at $14,238,700 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,954,472 shares of ARS Pharmaceuticals, Inc.. This represents a change in shares of -9.28% during the quarter. The current value of the position is $15,178,489 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (SPRY) in the form of stock options. The firm currently holds call options representing 52,000 of underlying shares valued at $417,560 USD and put options representing 14,700 of underlying shares valued at $118,041 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

SPRY / ARS Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARS PHARMACEUTICALS COM 82835W108 1,773,188 -181,284 -9.28 14,239 -37.47 0.0023
2026-02-17 2025-12-31 13F ARS PHARMACEUTICALS COM 82835W108 1,954,472 368,439 23.23 22,770 42.85 0.0034
2025-11-14 2025-09-30 13F ARS PHARMACEUTICALS COM 82835W108 1,586,033 -656,143 -29.26 15,940 -59.26 0.0024
2025-08-14 2025-06-30 13F ARS PHARMACEUTICALS COM 82835W108 2,242,176 1,440,886 179.82 39,126 288.14 0.0068
2025-05-15 2025-03-31 13F ARS PHARMACEUTICALS COM 82835W108 801,290 -4,166 -0.52 10,080 18.63 0.0019
2025-02-14 2024-12-31 13F ARS PHARMACEUTICALS COM 82835W108 805,456 552,957 218.99 8,498 132.10 0.0015
2024-11-14 2024-09-30 13F ARS PHARMACEUTICALS COM 82835W108 252,499 161,741 178.21 3,661 374.22 0.0007
2024-08-14 2024-06-30 13F ARS PHARMACEUTICALS COM 82835W108 90,758 -21,307 -19.01 772 -32.58 0.0002
2024-05-15 2024-03-31 13F ARS PHARMACEUTICALS COM 82835W108 112,065 80,262 252.37 1,145 558.05 0.0002
2024-02-14 2023-12-31 13F ARS PHARMACEUTICALS COM 82835W108 31,803 20,265 175.64 174 304.65 0.0000
2023-11-14 2023-09-30 13F ARS PHARMACEUTICALS COM 82835W108 11,538 -208,810 -94.76 44 -97.09 0.0000
2023-08-14 2023-06-30 13F ARS PHARMACEUTICALS COM 82835W108 220,348 175,572 392.11 1,476 407.22 0.0003
2023-05-15 2023-03-31 13F ARS PHARMACEUTICALS COM 82835W108 44,776 36,479 439.66 291 315.71 0.0001
2023-02-14 2022-12-31 13F ARS PHARMACEUTICALS COM 82835W108 8,297 -89,173 -91.49 71 -86.41 0.0000
2022-11-14 2022-09-30 13F SILVERBACK THERAPEUTICS COM 82835W108 97,470 -134,196 -57.93 515 -47.56 0.0001
2022-08-15 2022-06-30 13F SILVERBACK THERAPEUTICS COM 82835W108 231,666 36,510 18.71 982 43.36 0.0003
2022-05-16 2022-03-31 13F SILVERBACK THERAPEUTICS COM 82835W108 195,156 101,591 108.58 685 9.95 0.0001
2022-02-14 2021-12-31 13F SILVERBACK THERAPEUTICS COM 82835W108 93,565 19,073 25.60 623 -16.15 0.0001
2021-11-15 2021-09-30 13F SILVERBACK THERAPEUTICS Cmn 82835W108 74,492 39,844 115.00 743 -30.56 0.0002
2021-08-16 2021-06-30 13F SILVERBACK THERAPEUTICS COM 82835W108 34,648 34,648 1,070 0.0002
2021-05-21 2021-03-31 13F/A-1 SILVERBACK THERAPEUTICS COM 82835W108 0 -138,138 -100.00 0 -100.00
2021-02-16 2020-12-31 13F SILVERBACK THERAPEUTICS COM 82835W108 138,138 138,138 6,401 0.0017
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ARS PHARMACEUTICALS COM Call 52,000 209.52 418 113.85 n/a n/a n/a
2026-02-17 2025-12-31 13F ARS PHARMACEUTICALS COM Call 16,800 13.51 196 31.76 n/a n/a n/a
2025-11-14 2025-09-30 13F ARS PHARMACEUTICALS COM Call 14,800 -18.23 149 -53.02 n/a n/a n/a
2025-08-14 2025-06-30 13F ARS PHARMACEUTICALS COM Call 18,100 -37.37 316 -13.22 n/a n/a n/a
2025-05-15 2025-03-31 13F ARS PHARMACEUTICALS COM Call 28,900 147.01 364 195.12 n/a n/a n/a
2025-02-14 2024-12-31 13F ARS PHARMACEUTICALS COM Call 11,700 350.00 123 232.43 n/a n/a n/a
2024-11-14 2024-09-30 13F ARS PHARMACEUTICALS COM Call 2,600 -87.06 38 -78.36 n/a n/a n/a
2024-08-14 2024-06-30 13F ARS PHARMACEUTICALS COM Call 20,100 -20.24 171 -33.46 n/a n/a n/a
2024-05-15 2024-03-31 13F ARS PHARMACEUTICALS COM Call 25,200 -21.25 258 46.86 n/a n/a n/a
2024-02-14 2023-12-31 13F ARS PHARMACEUTICALS COM Call 32,000 -34.83 175 -5.41 n/a n/a n/a
2023-11-14 2023-09-30 13F ARS PHARMACEUTICALS COM Call 49,100 22.75 186 -30.97 n/a n/a n/a
2023-08-14 2023-06-30 13F ARS PHARMACEUTICALS COM Call 40,000 6.38 268 9.84 n/a n/a n/a
2023-05-15 2023-03-31 13F ARS PHARMACEUTICALS COM Call 37,600 -5.05 245 -27.60 n/a n/a n/a
2023-02-14 2022-12-31 13F ARS PHARMACEUTICALS COM Call 39,600 224.59 338 426.56 n/a n/a n/a
2022-11-14 2022-09-30 13F SILVERBACK THERAPEUTICS COM Call 12,200 -80.10 64 -75.38 n/a n/a n/a
2022-08-15 2022-06-30 13F SILVERBACK THERAPEUTICS COM Call 61,300 260 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ARS PHARMACEUTICALS COM Put 14,700 -78.88 118 -85.43 n/a n/a n/a
2026-02-17 2025-12-31 13F ARS PHARMACEUTICALS COM Put 69,600 -45.75 811 -37.16 n/a n/a n/a
2025-11-14 2025-09-30 13F ARS PHARMACEUTICALS COM Put 128,300 29.99 1,289 -25.15 n/a n/a n/a
2025-08-14 2025-06-30 13F ARS PHARMACEUTICALS COM Put 98,700 -30.79 1,722 -3.96 n/a n/a n/a
2025-05-15 2025-03-31 13F ARS PHARMACEUTICALS COM Put 142,600 -38.13 1,794 -26.24 n/a n/a n/a
2025-02-14 2024-12-31 13F ARS PHARMACEUTICALS COM Put 230,500 42.99 2,432 4.02 n/a n/a n/a
2024-11-14 2024-09-30 13F ARS PHARMACEUTICALS COM Put 161,200 221.12 2,337 447.31 n/a n/a n/a
2024-08-14 2024-06-30 13F ARS PHARMACEUTICALS COM Put 50,200 19.52 427 -0.47 n/a n/a n/a
2024-05-15 2024-03-31 13F ARS PHARMACEUTICALS COM Put 42,000 -23.22 429 43.48 n/a n/a n/a
2024-02-14 2023-12-31 13F ARS PHARMACEUTICALS COM Put 54,700 -52.68 300 -31.42 n/a n/a n/a
2023-11-14 2023-09-30 13F ARS PHARMACEUTICALS COM Put 115,600 398.28 437 181.29 n/a n/a n/a
2023-08-14 2023-06-30 13F ARS PHARMACEUTICALS COM Put 23,200 954.55 155 1,007.14 n/a n/a n/a
2023-05-15 2023-03-31 13F ARS PHARMACEUTICALS COM Put 2,200 14 n/a n/a n/a
2022-11-14 2022-09-30 13F SILVERBACK THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-15 2022-06-30 13F SILVERBACK THERAPEUTICS COM Put 88,000 373 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.